drugset / Trial / NCT01701739

A Pharmacokinetics Study of Aleglitazar in Combination With Digoxin in Healthy Volunteers

NCT01701739

Phase 1 Completed 28 enrolled Hoffmann-La Roche
Non-randomizedSingle-groupOpen-label

Summary

This open-label, two-period, fixed-sequence study will investigate the pharmacokinetics and safety of multiple doses of aleglitazar on a single dose of digoxin in healthy volunteers. In period 1, volunteers will receive a single dose of digoxin, in period 2 volunteers will receive multiple doses of aleglitazar and a single dose of digoxin. The anticipated time on study treatment is one month.

Timeline

Start
2012-10
Primary completion
2013-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified
Subject aleglitazar Small molecule

Indications

No indication recorded.